In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
|Articles|February 16, 2022
AAMDS Upcoming Events: March 2022
AAMDSIF hosts Patient & Family Conferences around the United States each year.
Advertisement
2022 Patient and Family Hybrid Conference (San Antonio, TX)
March 26, 2022
8:30am – 3:30pm CT
AAMDSIF hosts Patient & Family Conferences around the United States each year. Conferences are free to attend and include presentations by the leading medical experts in rare blood cancers and bone marrow failure diseases. It is also an incredible and important opportunity for patients to connect with one another and share support, answers, and hope. Please join!
Advertisement
Related to this article
In the phase 3 ASAC trial, daily aspirin did not lower the risk of colorectal cancer returning after treatment for liver metastases, and serious side effects were more common.
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Challenge yourself after cancer by building healthier habits, strengthening relationships, managing stress and embracing new experiences for a healthier life.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.
Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.
Liver and bile duct cancer treatment has changed quickly since 2021, with new immunotherapy combinations, targeted pills and a new radiation option. Here's what's been approved and what it means for patients.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
FDA Withdraws Zepzelca Approval for Previously Treated Small Cell Lung Cancer
3
Life After Cancer: Challenge Yourself to Build Healthier Habits and Stronger Relationships
4
Rina-S Shows 45.9% Response Rate in Platinum-Resistant Ovarian Cancer
5